Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
We know for a fact Google will not have a robot - they said at time of the partnership that Google will not bring the robot, just the software, imaging etc. So that means that either Ethicon or JJDC (JnJ Innovation) will bring the surgical robotic platform. If I had to guess, since JJDC will own 23.6% of Warren Robotics compared to Ethicon (6.4%), it seems that JJDC will bring the surgical robotic platform. That means ethicon will bring the end effectors, sales and services and possible manufacturing of the robotic platform. If ethicon were bringing the robotic surgical platform then why only get 6.4% of Warren Robotics and why even have JJDC involved in Warren Robotics, let alone own 23.6% of Warren robotics? what do they bring that justifies that cut?
I don't think companies usually do PR when they hire someone, at least my company didn't release a PR when they hired me.
good article - wouldn't be surprised to see this in Titan SPORT
http://www.medgadget.com/2015/08/sonys-4k-and-3d-visualization-technology-to-help-improve-clinical-care-q-a.html
Also, this was posted on Transenterix website:
The SurgiBot System is currently in development and has not yet been cleared by the FDA for sale in the United States or by other regulatory authorities for sale outside the United States.
Did TRXC get up to $14 yet, that was their high. Aren't they going to dilute their shares again? that is coming soon.
If someone called u up on the phone and asked you for $3k, what would you do?
Taking a glance thru the patent, it looks like it is a access device around the incision area and this access device can be manipulated to fit different devices that need to access the body cavity. Certainly not a robotic system but looks like it can be used at the incision area.
the ownership stakes in the JV
the submited document to the CCI approval - very interesting
http://www.cci.gov.in/May2011/OrderOfCommission/CombinationOrders/C-2015-06-283.pdf
That's why they FDA held these discussions that included Fowler and top robotic surgeons in the country b/c they don't want to standardize if it will limit competition or innovation. An example is that Titan's ($TITXF) snake arms is such an advancement over the davinci wristed straightrod arms, that making all RASD straightrod to help with uniformity and training wouldn't make sense. Imagine if we all were still driving model T cars. IMO, my takeaway from the webcast is that the FDA understands that standardization/uniformity is not good.
I just went thru Part 1 of Day two (where fowler and park were panelist). I don't have the proper perspective to tell why fowler mentioned that other than the fact that not all Robotic Platforms will be the same, much like not all medical devices are the same even though they are used for a similar procedure. It could have been around the idea of: should all robotic platforms be the same and therefore all training be the same and the resounding feedback from physicians was no. When Titan comes to market, they will have to have training programs in place to help physicians become proficient with SPORT. Just b/c a physicians has worked on davinci for 5 years doens't mean they don't need any training on SPORT.
It makes sense, davinci is the straight arms and Titan will be snake like arms, davinci has a console that you look into and Titan will have the 3D monitor, davinci's hand/foot controls will operate differently than SPORT.
I just found it interesting that he mentioned the time surgeons have spent on SPORT already and what they have learned from that. Maybe one of them was Lefty and he was knocking knuckles with the big boys.
Guy from Ximedica makes an appearance and talks about their role in helping FDA in evaluating products for approval (2:26:45)
Fowler also makes some interesting comments at the 2:05:41 mark about Titan and how they have had a number of surgeons already on and using SPORT. The question posed was should all Robotic Platforms be standardized? Fowler said that the not all skills acquired on davinci would be transferrable and that training is crucial on any new device.
They are, at the 1:22:15 mark - he mentions his role with Titan and that they are developing a RASD. What jumps out on day 2 is the importance that will be put on training/simulation
First info out of FDA, good to see a TITXF Advisory Board Surgeon quoted in article.
http://www.fiercemedicaldevices.com/story/docs-tell-fda-regulate-robotic-surgery-cautiously-anticipation-competitors/2015-07-28
TRXC down from $14/share with more dilution coming.
Interesting when you read thru JnJ earnings conf call with the CEO Alex Gorsky, he says that whatever JnJ is in they will either be one or two in the market in that arena. So most likely whatever JnJ/Google has planned for Robotic Surgery, you can be sure that their goal is to be #1 or #2 in that space. At least that rules out TRXC.
that's mr. taco to you.
Trxc would have to be 500% to get back to its high of $14/share, I believe it's at $3.15 or so. Product delayed as well plus mor dilution coming. Being in a stock like trxc w little upside and no definitive launch date, soon to be antiquated technology.
At least w titxf, it's nice to have the chief scientific officer, Dennis fowler, be on a panel which involves the FDA and the future of robotic surgery
I would agree with that and believe that the unveiling of SPORT will include a single port and multi port platform.
on another note, it looks like TRXC was at $14/share at one point and it will be half a decade til it gets back to that point.
Laviolette isn't helping trxc much, they were supposed to be in market now but it won't be until 2016 at earliest. Imo, they will struggle with what comes out of fda meeting on Monday and Tuesday. I would continue to expect delays from trxc. I noticed no openings for any sales, marketing people in their career section.. It looks the same from 3 months ago, still trying to fill positions that have been opened for awhile
With the recent announcement of the Shelf Offering of $45M, it now appears that Titan has access to $135M if it needs it (shelf offering and warrants). As someone pointed out to me yesterday, that is actually good news and a shelf offering of $45M is not going to just be granted to an OTC stock if does not have great potential value. Apparently this will also give Titan more leverage as they pursue M&A.
The only reason to panic is if u r a day trader or market manipulator. If ur long, which I am, no need for panic. The industry numbers point to huge oppty but I have to stick to my timeline - end of 2016.
Also, anyone who is long KNEW this summer would behave just like this, with nothing tangible til Q4 what else could u expect.
Been adding the last month and have gotten my cost basis down by .15 cents a share
At least one multi-port robotic system, possibly 2
here's something to think about (cat out of the bag?):
It is possible that Titan has also been working on bringing back the concept of Amadeus so that when they launch SPORT to the market, they will also be able to provide a multi-port platform as well. Think about this, in Nov Titan says that "voice of customer" wants more indications (to capture 4,000,000 procedures annually) for SPORT. If Titan only has the Single Port available, sure the customer would like that single port but they would also need to keep a multi-port platform around for the highly complicated and complex robotic procedures. Now they would have to keep a SPORT and a Da Vinci HOWEVER, if SPORT is easily able to change from a single port to a multi-port to capture both spectrums of the robotic surgeries while also being mobile and less expensive then they have a game changer. Announcing in October (Q4) that they will also have a multi-port platform available for the clinical trials would certainly be of high value to the market and potential acquirer.
For those who are interested, check out the Titan patents, from the drawings it looks like the booms can be added to create multiple arms (hence going from single to multi-port) very easily. I am not an engineer and if we have any on the board, i'd like to hear their feedback on the patent info.
Yea, these guys (hargrove, pope, frost) running these companies are jokes and don't know what they are doing, how could they have all carved out incredible careers in the medical device field? 10, 20, 30 years with successful track records doesn't mean squat if they don't give me a press release now.
Some people are good at putting 500-1000 piece puzzles together and others get frustrated after 10 pieces. The robotic surgery market and Titan and JnJ/Google is a 1000 piece puzzle and I can see why it is frustrating for some.
IMO, The "connections" that Titan mgmt has is one of the reasons I am still invested in Titan, along with Ximedica and the Surgeon Advisory Board.
Ted, can u break down wahlburgers stock for me?
In my very limited experience of M&A, one thing always stood out to me was how quiet things got regarding news, PR, etc and how tight lipped everyone involved got. This of course is looking back at the situation but based on that experience, I find it oddly comforting that Titan is so quiet and so is the JnJ/Google partnership. To me that tells me that things are really going on underneath the surface, JMHO.
Interesting how the opposite is true when you have these rumors of takeovers or M&A (i.e. Twitter) and how the stock reacts and fluctuates.
To share some of my thoughts on it as well: It sheds light on why they have been so tight lipped about the product and why they haven't shown many video's, pictures, etc of Titan SPORT. A competitor can't really bring a potential IP suit if they have nothing tangible to pursue. It gives me some explanation of why mgmt has been so quiet - don't give the competitor something that could slow Titan/Ximedica's process down by diverting the attention from development to fending off IP suits. Also, having a guy like Jasminder on the Titan team also helps provide me with confidence that Titan/Ximedica are taking the necessary steps in each stage of the process. Also, is interesting too that ISRG would pull their single port right now - IMO, maybe Titan's IP on Single Port Technology is stronger than ISRG and they know it.
I got a chance to listen to the audio of the IP conference with Jasminder Brah of Titan.....WOW! Thanks for the tip, what a great find, it helped add another layer of information for me that continues to support my investment in Titan. I have been very, very impressed with the personnel involved in Titan and Jasminder is right at the top (obviously his peers at Medtronic/Covidien think so too if you listen to their reactions to his answers).
My favorite screen names: Jabberwocky, El Guapo Roboto, Katalyst89. When Titan hits, I look forward to meeting them in Vegas
Thanks TED. Any chance you are a talking teddy bear?
I finally had a chance to go thru the transcript of the JnJ conf call and IMO, I couldn't be more excited about my investment in Titan. In reading b/t the lines of the answers given by Alex, Dominic and Sandy, it was very telling for me that their venture into Robotic Surgery will be thru M&A. The collaboration with Google will only enhance the platform they bring to market. There is the chance that they could decide to purchase another robotic system that isn't Titan(although I can't even imagine what other company it could be and they gave no indication whatsoever they were developing a robotic system) but based on what I read, I am adding Titan big time. I am still strong and believing that it won't be long anymore.
$TITXF
Great article about Titan, really seems that they are right on the precipice. Looks like Software will play a huge role in Titan SPORT. It is interesting that we have a medical device in Titan SPORT that will have a huge software component to it. Then it is interesting reading news that J&J (medical device) will partner with Google (Software) in bringing the next generation surgical robotic platform to the market.
The only problem I have and what gives me pause is that it seems too obvious.
Question for surgeons: in the article, Dennis Fowler mentions nagivation with Titan Sport, does da vinci have a strong navigational component to their platform? Thanks for the info.
$TITXF
Good points Bristol19, quick question for you, do you think Ximedica will ever hire engineers?
LTG must use a dart board to decide what info to use and its all wrong
*JNJ/Google is 3 years away
*Big Companies don't buy start ups
*SurgiBot is a surgical robotic platform
*No big company has ever bought a development company w/ no revenue
and on and on.
http://www.ximedica.com/Solutions/CaseStudies.aspx#62761-titan-medical-sport-surgical-system
$TITXF - still front and center on Ximedica's list of acheivements - IMO, heavy lifting of development could be completed. Probably why $TITXF has signed an agreement with a global supplier of custom end effectors and an agreement with prestigious SAIL Training Center at Anne Arundel Health System
This is an interesting article about "Big Companies" and "Startups". Of course someone like LTG obviously could never find or understand the concept of this b/c his research consists of...uh, nothing. I had to read his post several times b/c I couldn't believe someone would expose themselves like that and show how little knowledge they have about a subject matter.
http://www.theatlantic.com/sponsored/siemens/corporate-goliaths-and-start-up-davids-join-forces-to-invent-the-future/437/
LTG, that post isn't for you. I wouldn't trust someone like you who pump a stock only to lose hundreds of thousands of dollars for those who invested in TRXC (remember when it was $14/share and they are diluting again). But I forgot, its not about you, you want to do right by all those that you post for. Your comment that big companies don't buy small companies is so wrong and shows that you have no idea how to do research.
Does anyone know if J&J/Ethicon has anyone internally that is overseeing their Robotics program? They must have someone in a role like that and that might help provide some insight into their actions. The job postings that were put out were for people to work on robotic system but they didn't appear to be internal development. That would imply that they must have someone who is overseeing this (who these new employees would report to) and maybe that person is in place to work with bringing on a robotic system rather than develop a robotic system.
Also, i would imagine that Ethicon would have some lead scientific officer that would also be overseeing either the development of a robotic system or the acquisition of a robotic system. It would be interesting if we could find out more about the person and their responsibilities. Again, it could provide insight into what is going on. IMO